Alexandra C Chadwick1, Kiran Musunuru2,3. 1. Cardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 2. Cardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. kiranmusunuru@gmail.com. 3. Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. kiranmusunuru@gmail.com.
Abstract
PURPOSE OF REVIEW: Clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated 9 (Cas9) has recently emerged as a top genome editing technology and has afforded investigators the ability to more easily study a number of diseases. This review discusses CRISPR/Cas9's advantages and limitations and highlights a few recent reports on genome editing applications for alleviating dyslipidemia through disruption of proprotein convertase subtilisin/kexin type 9 (PCSK9). RECENT FINDINGS: Targeting of mouse Pcsk9 using CRISPR/Cas9 technology has yielded promising results for lowering total cholesterol levels, and several recent findings are highlighted in this review. Reported on-target mutagenesis efficiency is as high as 90% with a subsequent 40% reduction of blood cholesterol levels in mice, highlighting the potential for use as a therapeutic in human patients. The ability to characterize and treat diseases is becoming easier with the recent advances in genome editing technologies. In this review, we discuss how genome editing strategies can be of use for potential therapeutic applications.
PURPOSE OF REVIEW: Clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated 9 (Cas9) has recently emerged as a top genome editing technology and has afforded investigators the ability to more easily study a number of diseases. This review discusses CRISPR/Cas9's advantages and limitations and highlights a few recent reports on genome editing applications for alleviating dyslipidemia through disruption of proprotein convertase subtilisin/kexin type 9 (PCSK9). RECENT FINDINGS: Targeting of mousePcsk9 using CRISPR/Cas9 technology has yielded promising results for lowering total cholesterol levels, and several recent findings are highlighted in this review. Reported on-target mutagenesis efficiency is as high as 90% with a subsequent 40% reduction of blood cholesterol levels in mice, highlighting the potential for use as a therapeutic in humanpatients. The ability to characterize and treat diseases is becoming easier with the recent advances in genome editing technologies. In this review, we discuss how genome editing strategies can be of use for potential therapeutic applications.
Authors: F Ann Ran; Patrick D Hsu; Chie-Yu Lin; Jonathan S Gootenberg; Silvana Konermann; Alexandro E Trevino; David A Scott; Azusa Inoue; Shogo Matoba; Yi Zhang; Feng Zhang Journal: Cell Date: 2013-08-29 Impact factor: 41.582
Authors: Gaelen T Hess; Laure Frésard; Kyuho Han; Cameron H Lee; Amy Li; Karlene A Cimprich; Stephen B Montgomery; Michael C Bassik Journal: Nat Methods Date: 2016-10-31 Impact factor: 28.547
Authors: Max A Cayo; Sunil K Mallanna; Francesca Di Furio; Ran Jing; Lauren B Tolliver; Matthew Bures; Amanda Urick; Fallon K Noto; Evanthia E Pashos; Matthew D Greseth; Maciej Czarnecki; Paula Traktman; Wenli Yang; Edward E Morrisey; Markus Grompe; Daniel J Rader; Stephen A Duncan Journal: Cell Stem Cell Date: 2017-04-06 Impact factor: 24.633
Authors: Qiurong Ding; Alanna Strong; Kevin M Patel; Sze-Ling Ng; Bridget S Gosis; Stephanie N Regan; Chad A Cowan; Daniel J Rader; Kiran Musunuru Journal: Circ Res Date: 2014-06-10 Impact factor: 17.367
Authors: Prashant Mali; John Aach; P Benjamin Stranges; Kevin M Esvelt; Mark Moosburner; Sriram Kosuri; Luhan Yang; George M Church Journal: Nat Biotechnol Date: 2013-08-01 Impact factor: 54.908
Authors: Lili Wang; Camilo Breton; Claude C Warzecha; Peter Bell; Hanying Yan; Zhenning He; John White; Yanqing Zhu; Mingyao Li; Elizabeth L Buza; Derek Jantz; James M Wilson Journal: Mol Ther Date: 2021-02-18 Impact factor: 12.910
Authors: Diana C Mantilla-Escalante; María-Carmen López de Las Hazas; Judit Gil-Zamorano; Lorena Del Pozo-Acebo; M Carmen Crespo; Roberto Martín-Hernández; Andrea Del Saz; Joao Tomé-Carneiro; Fernando Cardona; Isabel Cornejo-Pareja; Almudena García-Ruiz; Olivier Briand; Miguel A Lasunción; Francesco Visioli; Alberto Dávalos Journal: Nutrients Date: 2019-06-13 Impact factor: 5.717